It’s been a few years since Brexit, and pharmaceutical companies have been adapting their therapy development plans as regulatory guidelines for different regions get updated. Health technology assessments or HTAs remain one area where the divergence of reimbursement frameworks in the UK and European Union is expected to impact how and when new therapies become available in those regions.
In this month’s issue, we take a look at how market access following an evolving process to conduct HTAs is expected to change in the near future in the UK.
Go deeper with GlobalData
Also, in this issue, we tackle the sparse research landscape for treatments for prion diseases and whether all generic manufacturers can pivot to producing specialty and complex generics.
Do catch the guest columns on digital health in pharma, and how collaborative research has led to new ways for studying long Covid.
All this, and the latest pharma industry news, comment, data, and analysis from GlobalData.
See Also:
Read the latest issue of Pharma Technology Focus for all this and more news, insights, data and analysis from the pharmaceutical industry.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataYou can also subscribe here to receive email notifications when a new issue is available.
